Sermorelin
No third-party certificate is currently published for this product.
Sermorelin (10mg) — Research Peptide
Sermorelin at 10mg per vial provides researchers with a higher-dose format of this GHRH 1-29 analogue for extended protocols, dose-response studies, or multi-arm experimental designs. Sermorelin is the most clinically studied truncated GHRH analogue, with an established research record spanning GH axis physiology, body composition research, and clinical trials in GH deficiency and age-related GH decline.
Research Significance
Sermorelin’s clinical research history includes FDA-approved formulations (Geref) for GH deficiency diagnostics and paediatric GH deficiency treatment, providing a regulatory-grade research foundation rarely available for investigational peptides. Published clinical data from multiple Phase 3 programmes document dose-dependent GH stimulation, IGF-1 elevation, and body composition effects in both paediatric and adult populations.
In contemporary research, sermorelin serves as an important comparator compound alongside longer-acting GHRH analogues (CJC-1295) and GHRP combinations (ipamorelin), enabling researchers to isolate the contribution of pulse duration versus pulse frequency versus pulse magnitude to GH axis outcomes.
Product Specifications
- Peptide: Sermorelin (GHRH 1-29)
- Dose: 10mg per vial
- Format: Lyophilised powder, bulk box of 10 vials
- Purity: ≥98% Janoshik HPLC verified
- Storage: -20°C. 24-month stability.
For laboratory research use only. Not for human therapeutic use.
